Melanoma: An Overview of Introduction, Types, Pathogenesis,Lab

Introduction

Table of Contents

Melanoma is the most aggressive and invasive type of skin cancer. It originates from melanocytes, the specialized pigment-producing cells located in the basal layer of the epidermis. While it accounts for less than 5% of all skin cancer cases, it is responsible for over 90% of skin cancer-related deaths. Melanoma primarily manifests on the skin but can also develop in other tissues containing melanocytes, such as the eyes (uveal melanoma) and mucous membranes.

Types of Melanomas

Cutaneous melanoma is classified into four primary clinical and pathological subtypes:

Superficial Spreading Melanoma: Most common type (~70% of cases); grows horizontally along the top skin layer before penetrating deeper.
Nodular Melanoma: Second most common type (15–30%); aggressive variant that bypasses the horizontal phase, growing vertically as a firm, dark bump.
Lentigo Maligna Melanoma: Accounts for 4–10% of cases; develops from pre-existing sun freckles on chronically sun-exposed areas like the face in older adults.
Acral Lentiginous Melanoma: Occurs on palms, soles, or under nail beds; accounts for 2–8% in fair-skinned individuals but up to 60% in darker-skinned individuals.

Pathogenesis

The development of melanoma involves a multi-step interaction between environmental triggers and genetic mutations.

[UV Radiation / Genetic Risk] – [DNA Damage in Melanocytes] -[Hyperactivation of MAPK Pathway (BRAF / NRAS mutations)] -[Uncontrolled Cell Proliferation] – [Radial Growth Phase]- [Vertical Growth Phase / Metastasis]

UV Radiation Damage: Ultraviolet (UV) light from sunlight or tanning beds induces direct DNA damage and oxidative stress in melanocytes.
Oncogenic Pathways: DNA damage leads to critical mutations that hyperactivate the mitogen-activated protein kinase (MAPK) pathway. Mutations in the BRAF gene (especially V600E) are present in roughly 50% of cutaneous melanomas. Other common mutations occur in the NRAS and KIT genes.
Growth Phases: Melanoma typically transitions from a Radial Growth Phase (horizontal proliferation within the epidermis) to a Vertical Growth Phase (invasion down into the dermis), which provides access to vascular and lymphatic networks for metastasis.

Laboratory and Clinical Diagnosis

1. Clinical Evaluation (The ABCDE Rule)

Clinicians and patients utilize the ABCDE criteria to identify suspicious pigmented lesions:

A – Asymmetry: One half of the lesion does not match the other.
B – Border Irregularity: Edges are ragged, notched, or blurred.
C – Color Variation: Shading is not uniform; it contains patches of black, brown, tan, red, or white.
D – Diameter: The lesion is larger than 6 mm (the size of a pencil eraser).
E – Evolving: The mole is changing in size, shape, color, or is bleeding/itching.

2. Histopathological Confirmation

Excisional Biopsy: Gold standard diagnostic method. A full-thickness complete excision with a narrow clinical margin is performed to preserve tumor architecture.
Breslow Thickness: The absolute vertical measurement of the tumor from the top of the granular layer to the deepest area of invasion. It is the single most critical prognostic factor.
Immunohistochemistry (IHC): Pathologists use diagnostic biomarkers like S100, HMB-45, Melan-A/MART-1, and SOX10 to confirm melanocytic origin in challenging or amelanotic cases.

3. Molecular Testing

Per current ESMO Clinical Practice Guidelines, BRAF V600 mutation testing is mandatory for all advanced or resectable Stage III/IV patients to guide targeted systemic selection.

Treatment Modalities

Stage	Primary Treatment Options	Rationale / Notes
Early Stage (0 – II)	0.5–1 cm margin for in situ tumors; 1–2 cm margins for invasive tumors, depending on Breslow depth.	0.5–1 cm margin for in situ tumors; 1–2 cm margins for invasive tumors depending on Breslow depth.
Locoregional (Stage III)	WLE + Sentinel Lymph Node Biopsy (SLNB)	If SLNB is positive, treatment involves adjuvant systemic therapy (immunotherapy or targeted therapy).
Advanced / Metastatic (Stage IV)	Systemic Therapy (First-line)	Immunotherapy (Anti-PD-1 like pembrolizumab, or anti-CTLA-4 combinations) or Targeted Therapy (BRAF/MEK inhibitors for BRAF-mutant cases).

Prevention

UV Protection: Apply broad-spectrum sunscreen (SPF 30 or higher) daily, reapply every two hours, and wear protective clothing.
Avoid Artificial UV: Avoid indoor tanning beds completely, as they emit highly concentrated UV radiation.
Regular Screenings: Perform monthly skin self-examinations using the ABCDE rule and get annual full-body evaluations from a dermatologist.

Keynotes

Melanoma Source: Arises from melanocytes; mostly cutaneous but can be mucosal or ocular.
Prognostic Factor: Breslow thickness dictates the clinical stage and overall survival probability.
Key Driver Mutation: BRAF V600 mutations alter the MAPK pathway in nearly half of all cases.
Biopsy Mandate: Partial or shave biopsies are discouraged; a complete excisional biopsy is required for definitive staging.
Modern Standard of Care: Advanced stages are primarily treated with immunotherapy (immune checkpoint inhibitors) rather than conventional chemotherapy.

Melanoma: An Overview of Introduction, Types, Pathogenesis,Lab Diagnosis, Treatment, Prevention, and Keynotes

Introduction

Types of Melanomas

Pathogenesis

Laboratory and Clinical Diagnosis

Prevention

Keynotes

Further Readings

Read Also...

Leave a Comment Cancel reply